IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stefan Berg, et al.

Serial No.: 10/539,543

Group Art Unit: To Be Determined

Filing Date: June 16, 2005

Examiner: To Be Determined

For: Novel Compounds Having Selective Inhibiting Effect at GSK3

MAIL STOP PCT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed. The Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PRO Forms SB/08A and SA/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

	within three months of the filing date of the patent.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the International Application.
\boxtimes	before the mailing date of a first Office Action on the merits.

	date o	the mailing date of a first Office Action on the merits, but before the mailing f a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance 37 C.F.R. § 1.311, and accordingly is accompanied by:
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
		or
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
		no fee is owed by the applicant(s).
	being and ac	ordance with 37 C.F.R. § 1.129(a), the Information Disclosure Statement is filed in connection with the first or second After Final Submission, ecordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see ment" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p) is ed.
] .	Notice Fee, a	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a e of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), Statement", and "Fees" below).
\boxtimes	attachenclos for Int	s of the references (excluding the US Patent Documents) listed on the ed PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449, are sed including a copy of the International Search Report dated April 20, 2004 ternational Application No. PCT/SE2003/001955 and International-Type in Report dated September 10, 2003.
	EXC	EPT THAT:
		In view of the voluminous nature of reference, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the US Patent and Trademark Office in the patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement und	er 37	C.F.R.	§ :	1.97(e))
---------------	-------	--------	-----	-------	----	---

	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more that three months prior to the filing of the Information Disclosure Statement.					
Fees						
\boxtimes	No fee is owed by the applicant(s).					
	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.					
Metho	od of Payment of Fees					
	Attached is a check in the amount of \$ This form is submitted in duplicate.					
	Charge Deposit Account No. 26-0166 in the amount of \$180.00. This form is submitted in duplicate.					
\boxtimes	Please charge any deficiency or credit any overpayment of Deposit Account 26-0166.					
	No fee or Statement is required under 37 C.F.R. § 1.97(b).					
	Respectfully submitted,					
	La H. Londen!					

Dated: 9/29/05

Raren H. Kondrad Registration No.: 38,212

Address Associated with Customer Number: 22466

JC06 Rec'd PCT/PTO 03 OCT 2005

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 19	995, no persons are required to respond to a colle	atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action of information unless it displays a valid OMB control number.						
(Application Number	10/539,543						
TRANSMITTAL	Filing Date	June 16, 2005						
FORM	First Named Inventor	Stefan Berg						
	Art Unit	To Be Determined						
(to be used for all correspondence after ini	Examiner Name	To Be Determined						
Total Number of Pages in This Submission	6 Attorney Docket Number	100925-1 US						
The same of the sa		100723-1 03						
ENCLOSURES (Check all that apply)								
Fee Transmittal Form Fee Attached	Drawing(s) Licensing-related Papers	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences						
Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request X Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Form PTO SB/08a and Form PTO SB/08b, 5 References, Copy of International Search Report and International -Type Search Report for International Application No. PCT/SE2003/001955						
SIGN Firm Name	ATURE OF APPLICANT, ATTOR	NEY, OR AGENT						
AstraZeneca Phar	maceuticals							
Signature Kauen A	1. Knided							
Printed name Karen H. Kondrad								
Date Sept. 2	9, 2005 Re	eg. No. 38,212						
CERTIFICATE OF TRANSMISSION/MAILING								
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Market M Melacul								
Typed or printed name Marie M. C		Date 14/29, 2005						
This collection of information is required by 37 C	ED 4.6. The information is assurant to the con-							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

	bstitute for form 1449A/PTO	no persons are		espond to a collection of information unless it contains a valid OMB control number. Complete if Known		
-				Application Number	10/539,543	
IN	NFORMATION DISC	CLOSUE	RE	Filing Date	06/16/2005	
	TATEMENT BY AP			First Named Inventor	Stefan Berg	
	OTATEMENT BY ALL EIGANT		••	Art Unit	To Be Determined	
(Use as many sheets as necessary)				Examiner Name	To Be Determined	
Sheet	1	of	1	Attorney Docket Number	100925-1 US	

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	^{US-} 6255307 B1	July 3, 2001	Brian Cox, et al.	
	AB		October 18, 2001	Karl Schoenafinger, et al.	
		US-			
		US- ,			
		US-			Transition (a)
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No.'	Country Co	ode ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°.			
	AC	wo	0168612 A2	Sept. 20, 2001	Cocensys, Inc.					
	AD	WO	02092585 A1	NOV. 21, 2002	Biovitrum AB					
	AE	wo	0160806 A2	Aug. 23, 2001	Neurogen Corp.					
	Ī									
	Ī	Ī	***************************************	***************************************	•	4 + 4 + 8 + 8 + 9 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

/ ,	Substitute for	form 1449B/PTO				Complete if Known	_
					Application Number	10/539,543	
	INFOF	RMATION D	ISCLO	SURE	Filing Date	06/16/2005	
	STAT	EMENT BY	APPLIC	CANT	First Named Inventor	Stefan Berg	
					Art Unit	To Be Determined	
		(Use as many sheets a	as necessary)		Examiner Name	To Be Determined	
	Sheet	1	of	1	Attorney Docket Number	100925-1 US	フ

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
	AF	International Search Report dated April 20, 2004 for International Application No. PCT/SE2003/001955						
	AG	International-Type Search Report dated September 10, 2003 for International Application No. PCT/SE2003/001955						
	АН	Caplus Accession no. 1997:637106, Document No. 127:293055, Saito, Tyota et al: "Solvent and substituent analogs"; & Journal of Chem Society, Perkin Transactions 2:Physical Organic Chemistry (1997), 9, 1711-1716						
	AI	Caplus Assession no. 1968:50943, Document No. 68:50943, Rakusan, J. et al: "Aromatic diazo and azo compounds ring"; & Collection of Czechoslovak Chemical Communications (1967), 32(8), 2882-9.						
	•							
	•••••							
		<u></u>						
<u> </u>	<u> </u>							

	1	1
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.